Twist Bioscience Corporation (TWST) Down 6.5% — Is It Time to Peel Out?
Twist Bioscience Corporation (TWST) is retreating in Tuesday's session, last trading at $191.65 on the NASDAQ — a $13.35 decline from the prior close of $205.00. The session has been unusually wide, with the stock swinging between $189.07 and $207.90, and the latest quote sits near the bottom of that band. Even after the pullback, TWST trades just 4.3% below its 52-week high of $200.31, reached on October 1, 2026, and roughly 723% above its 52-week low of $23.30. The steepness of that climb is the backdrop for everything happening in the shares right now.
Volume is tracking close to normal, with about 1.89 million shares traded so far against a 90-day average of roughly 1.89 million. Turnover has already matched a typical full session with trading still underway.
Why Twist Bioscience Corporation Price is Moving Lower
The clearest driver is a broad retreat across higher-growth Health Care names. Natera, Inc. (NTRA) fell 6.73%, Moderna, Inc. (MRNA) dropped 6.31%, and Revolution Medicines, Inc. (RVMD) slid 5.90%. TWST's 6.51% decline sits squarely within that range. When a cluster of biotech stocks moves this much in tandem, sector-level selling is the more convincing explanation than a single company event. Zoetis Inc. (ZTS), a steadier animal health name, edged up 0.28%, which suggests the pressure is concentrated in the more speculative corners of the sector.
TWST was especially exposed to that kind of rotation. As of October 5, the stock had climbed 534% year to date, and the average analyst price target stood at $115.27, far below a share price that was trading near $205. A gap that wide between the stock and Wall Street's consensus value leaves little cushion when sentiment turns. A stock carrying gains of that size can give back a meaningful slice on a risk-off day with nothing new on its own ledger. Profit-taking after a parabolic run fits both the sector pattern and Tuesday's intraday range of nearly $19.
The fundamentals behind the rally remain mixed. Twist's most recent report, released on August 3, showed fiscal Q3 revenue of $118.4 million. That beat the $114.54 million consensus and rose 23% year over year. The adjusted loss of $0.56 per share, however, was wider than the expected $0.48 loss, a reminder that growth is still costing the company money. Management raised its fiscal 2026 revenue guidance to $456 million to $457 million, up from $442 million to $447 million. That top-line momentum helps explain the run-up, but continued losses make the valuation harder to defend when the sector sells off.
What is the Twist Bioscience Corporation Rating - Should I Sell?
Weiss Ratings assigns TWST a D- rating. The rating was upgraded on 11/25/2025. Current recommendation is Sell. That upgrade nearly a year ago preceded the bulk of the stock's extraordinary advance. Yet the rating remains firmly in Sell territory, a sign that the share price has run well ahead of the underlying business quality.
The strengths are real but narrow. TWST is rated Excellent on the Total Return Index, which is no surprise for a stock that has risen from $23.30 to near $200 within a year. It is also rated Excellent on the Solvency Index, an important point for a company still posting losses. That rating indicates Twist has the balance sheet room to keep funding its operations without immediate financial strain. Its $11.83 billion market cap also gives it access to capital that many smaller life sciences peers lack.
Where the picture becomes more troubling is profitability. The Very Weak rating on the Efficiency Index reflects a -31.66% profit margin and trailing EPS of -$2.22. Those figures show a company that has not yet converted 23.24% revenue growth into earnings. The forward P/E of -84.85 signals that losses are expected to persist, so the stock's valuation rests entirely on future potential rather than current earnings power. The Growth Index is rated only Fair despite that double-digit top-line expansion. Sequential revenue growth of 6.9%, from $110.72 million in the March quarter to $118.38 million in the June quarter, is solid. Even so, the wider-than-expected adjusted loss shows that growth has not yet come with improving economics. The Weak Volatility Index is visible in Tuesday's session, where sector-wide selling pushed the stock through a range of $189.07 to $207.90. That kind of swing is the cost of owning a name priced so far above the analyst consensus.
Within the Health Care sector, Twist sits alongside Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), and Revolution Medicines, Inc. (RVMD, D-), all of which are sliding on Tuesday. Zoetis Inc. (ZTS, D) ranks slightly higher, though it too carries a Sell recommendation. The comparison underscores how widely Weiss's caution extends across this group.
About Twist Bioscience Corporation
Twist Bioscience Corporation (TWST) is a Health Care company that manufactures and sells synthetic DNA-based products. Incorporated in 2013 and headquartered in South San Francisco, California, the company supplies synthetic genes and gene fragments for product development across therapeutics, diagnostics, chemicals and materials, food and agriculture, and data storage. Its customers span biotech, pharmaceutical, industrial chemical, and agricultural companies as well as academic labs. Its oligo pools support targeted next-generation sequencing, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, and DNA data storage.
The NGS tools business has become a significant pillar of the company. It includes library preparation kits, human exome kits, fixed and custom panels, and alliance panels used in diagnostic tests, population genetics research, biomarker discovery, translational research, and microbiology. Twist also sells methylation detection kits for cancer and rare and inherited disease research, along with a fast hybridization and full RNA sequencing workflow. On the infectious disease side, it provides synthetic SARS-CoV-2 RNA reference sequences, synthetic monkeypox controls, and respiratory viral controls covering influenza, RSV, rhinoviruses, SARS, MERS, and coronaviruses. These sit alongside research tools such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel.
In drug discovery, Twist offers precision DNA libraries for antibody engineering, affinity maturation, and humanization. It also supplies immunoglobulin G proteins and an antibody optimization solution that tunes multiple characteristics of a given antibody at once. Strategic collaborations with bitBiome Inc. and Lilly TuneLab extend the platform into partnered discovery work. The breadth of applications built on a single DNA synthesis foundation is the company's core competitive advantage. It lets Twist serve research, clinical, and industrial customers from one manufacturing base while expanding its reach across the life sciences value chain.
Investor Outlook
Twist Bioscience Corporation (TWST) carries a Weiss Rating of D- (Sell). A 534% year-to-date run, an average analyst target near $115, and persistent losses make the stock highly vulnerable to further sector-driven pullbacks. Investors should watch whether fiscal Q4 results land within the raised $456 million to $457 million revenue guidance, and whether the adjusted loss begins to narrow rather than widen. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--